Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1β and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease

British Journal of Nutrition

Volumn 103, Issue 6, 2010, Pages 824-832

  Epstein, Jenny ^a   Docena, Guillermo ^a   MacDonald, Thomas T ^a   Sanderson, Ian R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Curcumin; IL 10; Inflammatory bowel disease; Matrix metalloproteinase 3; P38 Mitogen activated protein kinase

Indexed keywords

CURCUMIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; STROMELYSIN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHILD; COLON BIOPSY; CONTROLLED STUDY; DRUG MECHANISM; ENTERITIS; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; INTESTINE MUCOSA; MYOFIBROBLAST; ACETYLATION; ADOLESCENT; BIOPSY; CHEMISTRY; COLON; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; FIBROBLAST; METABOLISM; PHOSPHORYLATION;

CURCUMA LONGA;

ACETYLATION; ADOLESCENT; BIOPSY; CHILD; COLON; CURCUMIN; ENZYME ACTIVATION; FIBROBLASTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; MATRIX METALLOPROTEINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION;

EID: 77950363955     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114509992510     Document Type: Article

References (74)

1. Eaden JA, Abrams KR & Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48, 526-535.
2. Friedman S (2006) Cancer in Crohn's disease. Gastroenterol Clin North Am 35, 621-639.
3. Sawczenko A & Sandhu BK (2003) Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 88, 995-1000.
4. Logan RFA (1998) Inflammatory bowel disease incidence: up, down or unchanged? Gut 42, 309-311.
5. Goh K & Xiao SD (2009) Inflammatory bowel disease: a survey of the epidemiology in Asia. J Dig Dis 10, 1-6.
6. Montgomery SM, Morris DL, Pounder RE, et al. (1999) Asian ethnic origin and the risk of inflammatory bowel disease. Eur J Gastroenterol Hepatol 11, 543-546.
7. Heuschkel RB, Menache CC, Megerian JT, et al. (2000) Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 31, 8-15.
8. Bannerjee K, Camacho-Hubner C, Babinska K, et al. (2004) Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr 38, 270-275.
9. Lionetti P, Callegari ML, Ferrari S, et al. (2005) Enteral nutrition and microflora in pediatric Crohn's disease. JPEN 29 Suppl. 4, S173-S178.
10. Beattie RM, Bentsen BS & MacDonald TT (1998) Childhood Crohn's disease and the efficacy of enteral diets. Nutrition 14, 345-350.
11. Aggarwal S, Ichikawa H, Takada Y, et al. (2006) Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Molecular pharmacology 69, 195-206.
12. Singh S & Aggarwal BB (1995) Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloyl-methane) [corrected]. J Biol Chem 270, 24995-25000.
13. Bharti AC, Donato N & Aggarwal BB (2003) Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171, 3863-3871.
14. Rao CV (2007) Regulation of COX and LOX by curcumin. Adv Exp Med Biol 595, 213-226.
15. Goel A, Kunnumakkara AB & Aggarwal BB (2008) Curcumin as 'Curecumin': from kitchen to clinic. Biochem Pharmacol 75, 787-809.
16. Xu J, Fu Y & Chen A (2003) Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol 285, G20-G30.
17. Camacho-Barquero L, Villegas I, Sanchez-Calvo JM, et al. (2007) Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 7, 333-342.
18. Cho JW, Lee KS & Kim CW (2007) Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med 19, 469-474.
19. Lee CW, Lin WN, Lin CC, et al. (2006) Transcriptional regulation of VCAM-1 expression by tumor necrosis factor-alpha in human tracheal smooth muscle cells: involvement of MAPKs, NF-kappaB, p300, and histone acetylation. J Cell Physiol 207, 174-186.
20. Balasubramanyam K, Varier RA, Altaf M, et al. (2004) Curcu-min, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase- dependent chromatin transcription. J Biol Chem 279, 51163-51171.
21. Monteleone G, Del Vecchio Blanco G, Monteleone I, et al. (2005) Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease. Gastroenterology 129, 1420-1429.
22. Ongeri EM, Verderame MF & Hammond JM (2005) Follicle-stimulating hormone induction of ovarian insulin-like growth factor-binding protein-3 transcription requires a TATA box-binding protein and the protein kinase A and phosphatidyl-inositol-3 kinase pathways. Mol Endocrinol 19, 1837-1848.
23. White NR, Mulligan P, King PJ, et al. (2006) Sodium butyrate-mediated Sp3 acetylation represses human insulin-like growth factor binding protein-3 expression in intestinal epithelial cells. J Pediatr Gastroenterol Nutr 42, 134-141.
24. Holt PR, Katz S & Kirshoff R (2005) Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 50, 2191-2193.
25. Hanai H, Iida T, Takeuchi K, et al. (2006) Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4, 1502-1506.
26. Balasubramanyam K, Swaminathan V, Ranganathan A, et al. (2003) Small molecule modulators of histone acetyltransferase p300. J Biol Chem 278, 19134-19140.
27. Yoshida M, Kijima M, Akita M, et al. (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265, 17174-17179.
28. Ridley SH, Sarsfield SJ, Lee JC, et al. (1997) Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloprotei-nases, and IL-6 at different levels. J Immunol 158, 3165-3173.
29. Dean JL, Brook M, Clark AR, et al. (1999) p38 Mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J Biol Chem 274, 264-269.
30. Underwood DC, Osborn RR, Bochnowicz S, et al. (2000) SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 279, L895-L902.
31. Waetzig GH, Seegert D, Rosenstiel P, et al. (2002) p38 Mito-gen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 168, 5342-5351.
32. Lee JC, Kassis S, Kumar S, et al. (1999) p38 Mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials. Pharmacol Ther 82, 389-397.
33. Reinecker HC, Steffen M, Witthoeft T, et al. (1993) Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 94, 174-181.
34. Kang BY, Song YJ, Kim KM, et al. (1999) Curcumin inhibits Th1 cytokine profile in CD4\+ T cells by suppressing interleu-kin-12 production in macrophages. Br J Pharmacol 128, 380-384.
35. Jagetia G & Aggarwal B (2007) 'Spicing up' of the immune system by curcumin. J Clin Immunol 27, 19-35.
36. Zhang M, Deng CS, Zheng JJ, et al. (2006) Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis. Acta Pharmacol Sin 27, 1071-1077.
37. Jobin C, Bradham CA, Russo MP, et al. (1999) Curcumin blocks cytokine-mediated NF-kappa B activation and proinflam-matory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 163, 3474-3483.
38. Jurrmann N, Brigelius-Flohe R & Bol G-F (2005) Curcumin blocks interleukin-1 (IL-1) signaling by inhibiting the recruitment of the IL-1 receptor-associated kinase IRAK in murine thymoma EL-4 cells. J Nutr 135, 1859-1864.
39. Moore KW, de Waal Malefyt R, Coffman RL, et al. (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19, 683-765.
40. de Waal Malefyt R, Yssel H, Roncarolo MG, et al. (1992) Interleukin-10. Curr Opin Immunol 4, 314-320.
41. Fiorentino DF, Zlotnik A, Mosmann TR, et al. (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147, 3815-3822.
42. de Waal Malefyt R, Haanen J, Spits H, et al. (1991) Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174, 915-924.
43. Chomarat P, Vannier E, Dechanet J, et al. (1995) Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 154, 1432-1439.
44. Schreiber S, Heinig T, Thiele HG, et al. (1995) Immunoregula-tory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 108, 1434-1444.
45. de Waal Malefyt R, Yssel H & de Vries JE (1993) Direct effects of IL-10 on subsets of human CD4\+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 150, 4754-4765.
46. Asseman C, Mauze S, Leach MW, et al. (1999) An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190, 995-1004.
47. Groux H, O'Garra A, Bigler M, et al. (1997) A CD4\+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737-742.
48. Lindsay JO & Hodgson HJ (2001) Review Article: the immunoregulatory cytokine interleukin-10-a therapy for Crohn's disease? Aliment Pharmacol Ther 15, 1709-1716.
49. Pender SL, Breese EJ, Gunther U, et al. (1998) Suppression of T cell-mediated injury in human gut by interleukin 10: role of matrix metalloproteinases. Gastroenterology 115, 573-583.
50. Kuhn R, Lohler J, Rennick D, et al. (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75, 263-274.
51. Rennick DM & Fort MM (2000) Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(2/2) mice and intestinal inflammation. Am J Physiol 278, G829-G833.
52. Fahey AJ, Adrian Robins R & Constantinescu CS (2007) Curcumin modulation of IFN-beta and IL-12 signalling and cytokine induction in human T cells. J Cell Mol Med 11, 1129-1137.
53. Méndez-Samperio P, Trejo A & Perez A (2008) Mycobacterium bovis Bacillus Calmette-Guérin (BCG) stimulates IL-10 production via the PI3K/Akt and p38 MAPK pathways in human lung epithelial cells. Cell Immunol 251, 37-42.
54. Hickey FB, Brereton CF & Mills KH (2008) Adenylate cycalse toxin of Bordetella pertussis inhibits TLR-induced IRF-1 and IRF-8 activation and IL-12 production and enhances IL-10 through MAPK activation in dendritic cells. J Leukoc Biol 84, 234-243.
55. Chanteux H, Guisset AC, Pilette C, et al. (2007) LPS induces IL-10 production by human alveolar macrophages via MAPKi-nases-and Sp1-dependent mechanisms. Respir Res 8, 71.
56. Tone M, Powell MJ, Tone Y, et al. (2000) IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol 165, 286-291.
57. Hoang B, Trinh A, Birnbaumer L, et al. (2007) Decreased MAPK-andPGE2-dependent IL-11productioninGialpha2 2/2 colonic myofibroblasts. Am J Physiol 292, G1511-G1519.
58. Pender SL & MacDonald TT (2004) Matrix metalloproteinases and the gut-new roles for old enzymes. Curr Opin Pharmacol 4, 546-550.
59. Kruidenier L, MacDonald TT, Collins JE, et al. (2006) Myofibroblast matrix metalloproteinases activate the neutrophil chemoattractant CXCL7 from intestinal epithelial cells. Gastroenterology 130, 127-136.
60. Yodkeeree S, Garbisa S & Limtrakul P (2008) Tetrahydrocur-cumin inhibits HT1080 cell migration and invasion via downregulation of MMPs and uPA. Acta Pharmacol Sin 29, 853-860.
61. Saja K, Babu MS, Karunagaran D, et al. (2007) Anti-inflammatory effect of curcumin involves downregulation of MMP-9 in blood mononuclear cells. Int Immunopharmacol 7, 1659-1667.
62. Binion DG, Heidemann J, Li MS, et al. (2009) Vascular cell adhesion molecule-1 expression in human intestinal microvas-cular endothelial cells is regulated by PI 3-kinase/Akt/MAPK/NF-kappaB: inhibitory role of curcumin. Am J Physiol 297, G259-G268.
63. Binion DG, Otterson MF & Rafiee P (2008) Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 57, 1509-1517.
64. Chen YR & Tan TH (1998) Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 17, 173-178.
65. Collett GP & Campbell FC (2004) Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 25, 2183-2189.
66. Hu M, Du Q, Vancurova I, et al. (2005) Proapoptotic effect of curcumin on human neutrophils: activation of the p38 mitogen-activated protein kinase pathway. Crit Care Med 33, 2571-2578.
67. Wu CY, Hsieh HL, Sun CC, et al. (2008) IL-1 beta induces proMMP-9 expression via c-Src-dependent PDGFR/PI3K/Akt/p300 cascade in rat brain astrocytes. J Neurochem 105, 1499-1512.
68. Basu S, Pathak S, Pathak SK, et al. (2007) Mycobacterium avium-induced matrix metalloproteinase-9 expression occurs in a cyclooxygenase-2-dependent manner and involves phos-phorylation-and acetylation-dependent chromatin modification. Cell Microbiol 9, 2804-2816.
69. Lee CW, Lin CC, Lin WN, et al. (2007) TNF-alpha induces MMP-9 expression via activation of Src/EGFR, PDGFR/PI3K/Akt cascade and promotion of NF-kappaB/p300 binding in human tracheal smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 292, L799-L812.
70. Pender SL, Quinn JJ, Sanderson IR, et al. (2000) Butyrate upregulates stromelysin-1 production by intestinal mesenchymal cells. Am J Physiol 279, G918-G924.
71. Lao CD, Ruffin MTt, Normolle D, et al. (2006) Dose escalation of a curcuminoid formulation. BMC Complementary Altern Med 6, 10.
72. Chainani-Wu N (2003) Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 9, 161-168.
73. Sood A, Midha V, Sood N, et al. (2003) Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut 52, 1587-1590.
74. Thia KT, Loftus EV Jr, Sandborn WJ, et al. (2008) An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 103, 3167-3182.